Investigating Electrocardiographic Abnormalities in Patients with Coronary Microvascular Dysfunction

Abstract

BACKGROUND Coronary microvascular dysfunction (CMD) is a frequently overlooked and underdiagnosed mechanism of cardiac ischemia despite its heightened risk of major adverse cardiovascular events. The potential impact of CMD on the conduction system and occurrence of arrhythmias has received limited attention. This study aimed to examine the link between CMD and surface electrocardiography (ECG).

METHODS We harnessed the Coronary Microvascular Disease registry (CMDR), utilizing the CoroVentis CoroFlow System (Abbott) to invasively assess patients presenting with symptomatic chest pain. All patients underwent microvascular assessment of the left anterior descending artery territory. Our cohort was stratified into two groups, CMD-positive and CMD-negative, with an analysis of the most recent ECG performed prior to the invasive evaluation for each patient.

RESULTS Our cohort comprised 230 patients, of which 60 were classified as CMD-positive and 170 as CMD-negative. T-wave inversion was observed in 30.5% of CMD-positive patients compared to 20% in the CMD-negative group (P=0.09), and ST depression was identified in 6.7% of CMD-positive patients compared to 2.4% of CMD-negative patients (P=0.12). There were no differences in conduction disorders, such as left bundle branch block (LBBB), left anterior hemiblock (LAHB), left posterior hemiblock (LPHB), right bundle branch block (RBBB), incomplete right bundle branch block (ICRBBB), and bifascicular block, between the two groups. There were no discernible distinctions in the ECG intervals, including the PR, QRS, and QT. There was a trend of increased left ventricular hypertrophy (LVH) according to the ECG criteria in patients with CMD (11.7% vs. 5.3%; P=0.09).

CONCLUSION Our study revealed a tendency toward ischemic and hypertrophic ECG changes among CMD-positive patients, but no differences in the occurrence of conduction disorders in patients with and without CMD.

REGISTRATION URL: https://clinicaltrials.gov; Unique Identifier: NCT05960474

GRAPHIC ABSTRACT A graphic abstract is available for this article.

• Download figure
• Open in new tab

Graphic Abstract.

Clinical pathway for patients with chest pain undergoing ECG and coronary microvascular assessment, highlighting key findings, and insights.

WHAT IS KNOWN?

• Limited research has explored the impact of coronary microvascular dysfunction (CMD) on surface electrocardiogram (ECG) changes.

• The bolus thermodilution method has demonstrated efficacy for the invasive assessment of the coronary microvasculature in patients with symptomatic chest pain. These tools can aid in early detection and diagnosis of CMD.

WHAT THE STUDY ADDS

• In this study from the Coronary Microvascular Disease Registry (CMDR), higher rates of T-wave inversion and ST depression were observed in CMD-positive patients, providing valuable clinical insights. These ECG changes were similar to those observed in patients with stable angina.

• No difference in conduction disorders or ECG intervals was observed, although a greater tendency for left ventricular hypertrophy in CMD-positive patients suggests the importance of monitoring for cardiac structural changes and their potential association with CMD.

Competing Interest Statement

Disclosures Hayder D. Hashim reports serving on the advisory boards of, and being a speaker for, Abbott Vascular, Boston Scientific, and Philips IGT. Ron Waksman reports serving on the advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd.; being a consultant for Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd., Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc., and Venous MedTech; receiving institutional grant support from Amgen, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT; and being an investor in MedAlliance and Transmural Systems Inc. Brian C. Case Speaker: Zoll Medical. All other authors None.

Clinical Trial

Unique Identifier: NCT05960474

Funding Statement

None.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The design and conduct of the registry strictly adhered to the MedStar Health Institutional Review Board (IRB).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes